Insider Selling: Masimo Co. (NASDAQ:MASI) Director Sells $341,064.89 in Stock

Masimo Co. (NASDAQ:MASI) Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the transaction, the director now directly owns 16,581 shares of the company’s stock, valued at approximately $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Masimo Trading Up 1.5 %

NASDAQ:MASI opened at $168.21 on Monday. The company’s 50 day moving average price is $174.84 and its 200-day moving average price is $157.94. Masimo Co. has a 52 week low of $101.61 and a 52 week high of $194.88. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The stock has a market cap of $9.07 billion, a price-to-earnings ratio of 116.01 and a beta of 1.04.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $600.70 million for the quarter, compared to analysts’ expectations of $593.35 million. On average, equities research analysts forecast that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Masimo

Several institutional investors and hedge funds have recently added to or reduced their stakes in MASI. FMR LLC boosted its holdings in Masimo by 41.2% in the third quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock worth $900,860,000 after purchasing an additional 1,970,883 shares during the last quarter. Capital Research Global Investors boosted its holdings in Masimo by 80.5% in the fourth quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider’s stock worth $405,807,000 after purchasing an additional 1,094,647 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Masimo by 119.0% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider’s stock worth $286,823,000 after purchasing an additional 943,001 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in Masimo by 1,276.9% in the fourth quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider’s stock worth $156,604,000 after purchasing an additional 878,587 shares during the last quarter. Finally, Corient Private Wealth LLC boosted its holdings in Masimo by 8,847.1% in the fourth quarter. Corient Private Wealth LLC now owns 347,683 shares of the medical equipment provider’s stock worth $57,472,000 after purchasing an additional 343,797 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on MASI shares. Stifel Nicolaus restated a “buy” rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Piper Sandler upped their price objective on shares of Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Wells Fargo & Company upped their price objective on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Wednesday, February 26th. Finally, Raymond James upped their price objective on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Masimo has an average rating of “Moderate Buy” and a consensus target price of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.